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EDITORIAL
Brain barriers and brain fluid research 
in 2016: advances, challenges and controversies
Richard F. Keep1*, Hazel C. Jones2 and Lester R. Drewes3
Abstract 
This editorial highlights some of the advances that occurred in relation to brain barriers and brain fluid research in 
2016. It also aims to raise some of the attendant controversies and challenges in such research.
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Editorial
There continues to be a tremendous interest in brain bar-
riers and brain fluids research. Thus, for example, in 2016 
PubMed cites ~4000 papers on CSF, ~2950 papers on the 
blood–brain barrier (BBB)/neurovascular unit (NVU) 
and ~1200 papers on hydrocephalus. The purpose of 
this editorial is to highlight some of the advances made 
in 2016, as well as some of the attendant controversies. 
With regards to the latter, we also wish to highlight some 
of the challenges in such research. With the amount of 
research published in 2016, it is impossible to cover the 
breadth of important advances. The choices may seem 
idiosyncratic but hopefully useful.
Crossing the blood–brain barrier
One major aim of NVU/BBB research is to develop meth-
ods to improve the delivery of therapeutics to the brain. 
In that regard, there have been several advances in 2016. 
Deverman et  al. used Cre recombination-based adeno-
associated virus (AAV) targeted evolution (CREATE) to 
develop AAV capsids that better target the CNS [1]. That 
approach resulted in the generation of an AAV variant 
that widely transfected the mouse brain (neurons and 
astrocytes) after intravenous injection. The overall CRE-
ATE approach may greatly enhance gene transfer into the 
brain parenchyma for a variety of neurological conditions 
although there are some issues with the loading capacity 
of AAVs for large genes.
The delivery of proteins, including antibodies, at ther-
apeutic concentrations across the highly impermeable 
blood–brain interface has been a major impediment in 
the development of treatments for neurological condi-
tions. It is, therefore, noteworthy that Sevigny et  al. [2] 
using an antibody, aducanumab, that targets aggregated 
amyloid-β managed to achieve a brain:plasma area under 
the curve (AUC) of 1.3% and to dose-dependently reduce 
both brain soluble and insoluble amyloid-β in a mouse 
Alzheimer’s disease model. In addition, in a phase 1b 
clinical trial, aducanumab reduced brain amyloid-β and 
slowed clinical deterioration in Alzheimer’s patients.
The use of focused ultrasound in conjunction with 
intravenously administered microbubbles to disrupt 
endothelial cell tight junctions and enhance blood–brain 
permeability of therapeutics has been the focus of multi-
ple groups around the world (e.g. [3–5]). The feasibility 
of this approach has now been shown in non-human pri-
mates [5]. Focused ultrasound to enhance drug delivery 
is now in clinical trial for brain cancers (NCT02253212 
and NCT02343991). Considerable effort has been made 
in such studies to determine the safety window for the 
ultrasound. A concern is that the safety window may vary 
if the cerebrovasculature is impacted by a neurological 
condition (e.g. stroke), particularly as that impact may 
not be homogeneous. Interestingly, Cho et al. also found 
that focused ultrasound with microbubbles locally down-
regulated brain endothelial cell P-glycoprotein expres-
sion in rats [6]. This suggests that focused ultrasound can 
potentially impact brain drug delivery by both inducing 
structural changes and altering drug transport mecha-
nisms. It does, however, raise the question as to what 
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other endothelial properties, including gene expression, 
may be affected by the ultrasound. Overall, much effort 
is being directed towards enhancing delivery of therapeu-
tics to the brain using multiple approaches. The reader-
ship is referred to a recent volume of Drug Discov Today 
Technol [7] on some of those approaches.
Fluid flow within the brain
The concept of a glymphatic system was first proposed by 
Iliff et  al. [8]. It is proposed that there is a rapid move-
ment of CSF from the subarachnoid space into brain 
along the artery/arteriole paravascular space (linked to 
arterial pulsation), a movement of fluid from that space 
through the brain parenchyma where astrocyte aqua-
porin4 plays an important role, and a return of fluid to 
subarachnoid space along the paravascular space of ven-
ules/veins. This circulation may provide a way of clearing 
potentially toxic waste products, such as amyloid-β, from 
the brain. Since its first proposal, the concept of a glym-
phatic system has gained great traction with ~40 papers 
addressing glymphatics in 2016 alone (PubMed) and 
there have been excellent reviews on the subject [9–11]. 
It has been the spur for innovative research, including the 
impact of sleep on the system [12] and even its potential 
role in regards to the eye [13]. The application of ultrafast 
MRI techniques has led to the suggestion that in addition 
to arterial pulsations, low frequency vasomotor activity 
may provide assistance to glymphatic propulsion through 
the interstitial space [14] and also has enabled visualiza-
tion of the perivascular spaces with sub millimeter reso-
lution [15]. It should be noted, however, that there have 
been recent challenges to the concepts underlying the 
proposed glymphatic system in particular related to the 
role of arterial pulsation [16] and the role of astrocyte 
water permeability/aquaporin4 [17].
There also continues to be some controversy as the 
relative role of the choroid plexus in CSF production. 
The readership is referred to a number of recent reviews 
addressing that subject [9, 18–22]. In models of CSF flow 
there is generally a vectoral component (e.g. through the 
ventricular system), although there can be a large oscilla-
tion around that flow based on the respiratory and car-
diac cycles [23]. However, recent evidence shows that 
within the ventricular system there are complex flow 
patterns generated by cilia networks [24]. Interestingly, 
those flow patterns change not only spatially, but also 
temporally. These flow patterns may be important in reg-
ulating communication between different periventricular 
areas.
A related question to how much fluid is produced by 
the choroid plexus is how much fluid is produced across 
the cerebral capillaries, by what mechanisms, and how 
is fluid production affected by disease states? Fluid 
production and ion transport by cells of the NVU have 
been dealt with in depth in a recent review by Hladky and 
Barrand [19]. While such fluid transport cannot result 
from filtration across capillaries and needs to be linked to 
ion transport, defining the precise mechanisms involved 
(and how to manipulate them) has proven very difficult 
[19]. Studies of brain endothelial transport in  vivo are 
complicated by the presence of other components of 
the NVU. Perhaps progress can be made on vectoral ion 
and fluid transport with the newer generation of in vitro 
models with higher transendothelial electrical resist-
ance (TEER) and lower paracellular permeability (see 
below). Choroid plexus epithelial cell cultures with high 
TEERs have been used to demonstrate fluid transport 
[25]. An understanding of NVU/BBB fluid transport in 
disease states is vital for developing methods to reduce 
brain edema formation [26]. Methods of treating cerebral 
edema have not changed in decades.
Choroid plexus
Apart from fluid secretion and ion transport, there has 
been an upsurge in interest in other functions of the cho-
roid plexus. Evidence now indicates that it has important 
functions in immune surveillance [27], in stem cell regu-
lation [28] and in brain signaling via extracellular vesicles 
[29]. The choroid plexus may also be a potential route for 
drug delivery into the CSF by transcytosis [30].
Hydrocephalus
Fetal hydrocephalus can be induced in mice by intracer-
ebral injection of blood or lysophosphatidic acid (LPA) 
and such hydrocephalus can be blocked by an LPA recep-
tor antagonist [31]. Interestingly, Park et  al. [32] have 
recently investigated the molecular mechanisms underly-
ing LPA-induced hydrocephalus and found that LPA is an 
upstream regulator of the protein YAP which is impor-
tant in the development of ependymal junctions. Further 
dissection of these pathways may give insights into the 
potential causes of some forms of hydrocephalus.
Although congenital hydrocephalus can have non-
genetic causes, such as intraventricular hemorrhage, over 
100 genetic causes have now been identified [33]. Several 
biochemical pathways are implicated including Wnt sign-
aling, cell junction integrity and especially cilia function 
(e.g. [34, 35]). However, despite our advances in under-
standing underlying causes, shunt treatment or ven-
triculoscopy continue to be the only treatment available 
for hydrocephalus [36]. Despite efforts to improve shunt 
design, treatment still carries large risks.
Much effort continues to be directed towards idi-
opathic normal pressure hydrocephalus (iNPH) defined 
by enlarged ventricles and a triad of clinical signs in 
older people. Many theories of pathogenesis exist for this 
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complex condition and are comprehensively reviewed by 
Keong et al. [37]. Problems exist in distinguishing which 
patients will respond to shunt treatment (e.g. [38, 39]). A 
multimodal analysis including clinical signs, MRI param-
eters, intracranial pressure and CSF biomarkers did not 
predict shunt responders in a cohort of 284 patients [40]. 
Diffusion tensor imaging (DTI) has been used to deter-
mine white matter pathology in hydrocephalus [41] and 
changes after shunt treatment [42].
The blood–brain barrier/neurovascular unit 
in disease
Many neurological conditions are accompanied by BBB 
dysfunction (e.g. stroke, traumatic brain injury and brain 
neoplasms) with increased transfer of even proteins 
from blood to brain. There has always been a question 
of whether the BBB dysfunction is a secondary result of 
parenchymal injury or a primary site of injury. Recent 
results from Shi et  al. found that endothelial-specific 
overexpression of a mutant form of actin depolymerizing 
factor reduced barrier disruption after stroke and amelio-
rated acute and chronic brain injury [43]. These results 
strongly suggest that barrier dysfunction may be a cause 
rather than just result from parenchymal damage after 
stroke and that it is an important therapeutic target.
Currently, the only therapeutic intervention for 
ischemic stroke is thrombolysis-induced reperfu-
sion with tissue plasminogen activator (tPA) and now 
thrombectomy [44]. One major concern about the use 
of tPA to induce reperfusion is potential barrier dysfunc-
tion and hemorrhagic transformation. There has, there-
fore, been interest in combining tPA with an agent that 
protects the cerebrovasculature. Wahlgren et  al. [45] 
conducted a phase II randomized clinical trial combin-
ing intravenous thrombolysis with tPA and imatinib, 
an agent that protects the cells of the NVU and reduces 
hemorrhagic transformation in animal stroke models [46, 
47]. Wahlgren et al. found that imatinib was safe and that 
it showed some evidence of improved outcome in the 
stroke patients [45].
One function of brain endothelial cells is to supply 
essential nutrients to the brain. Thus, those cells express 
high levels of the glucose transport GLUT 1 (SLC2A1) 
and the large neutral amino acid transporter LAT1 
(SLC7A5). The importance of mutations in GLUT1 have 
long been known (glucose transporter type 1 deficiency 
syndrome; [48]) but Tarlungeanu et al. [49] have recently 
found that homozygous mutations in LAT1 are associ-
ated with autistic traits and that endothelial deletion of 
LAT1 in mice causes severe neurological defects that can 
be ameliorated by intracerebroventricular administration 
of branch-chain amino acids.
The use of serum (and CSF) biomarkers for neurologi-
cal conditions continues to be an area of intense research. 
For example, one particular focus has been the use of bio-
markers for diagnosis and prognosis in different grades of 
traumatic brain injury; e.g. concussion [50]. A recent arti-
cle by Dadas et al. [51] in Fluids Barriers CNS highlights 
the multiplicity of factors that impact biomarker levels in 
blood and presents modeling to enhance interpretation.
The cerebrovasculature has functions outside what are 
normally considered as ‘barrier’ properties. One such 
function is to form a vascular niche for neural stem cells 
promoting self-renewal and inhibiting differentiation [52] 
and there has been considerable interest in manipulat-
ing that niche to target cancer stem cells in glioblastoma 
and other brain cancers [53]. The cerebrovasculature 
can, however, also be a route for tumor invasion into 
surrounding tissue and Yadav et al. recently showed that 
such invasion can be reduced by targeting a chemokine 
receptor, CXCR4, improving survival in a mouse glioma 
model [54].
In vitro blood–brain barrier/neurovascular unit 
modeling
Helms et al. recently provided an excellent review of cur-
rent in vitro NVU/BBB models, their uses and limitations 
[55]. Progress continues to be made. Of note, Canfield 
et al. [56] recently showed that induced pluripotent stem 
cells (iPSCs) from a single patient can be used to derive 
endothelial cells, astrocytes and neurons and produce a 
BBB/NVU model with transendothelial electrical resist-
ances and permeabilities close to in  vivo. An ultimate 
goal for a number of groups is to produce microfluidic 
devices, a ‘BBB on a chip’ (e.g. [57–60]). An advantage of 
those models, as well some other larger scale models, is 
the incorporation of shear stress, an important determi-
nant of endothelial characteristics. Big strides are being 
made in developing in vitro NVU/BBB models with high 
TEERs and low passive permeabilities to hydrophilic 
molecules. A remaining challenge is whether those mod-
els can also recapitulate other NVU/BBB characteristics; 
e.g. relevant expression/activity of transporters and the 
metabolizing enzymes that form the metabolic barrier, as 
well as rates of transcytosis.
The future
As can be seen from this brief summary of just some 
of the research into the brain barriers and brain fluids, 
major strides have been made in 2016. It is a vibrant area 
of research and one that is always associated with areas 
of controversy. Technical advances are being made that 
will hopefully address those controversies and open new 
avenues for research.
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